Achieving directed immunostimulating complexes incorporation

References

• O'Hagan DT, Valiante NM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov.2, 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Barr IG, Sjölander A, Cox JC. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev.32, 247–271 (1998).
   PubMed Web of Science ®Google Scholar
• Morein B, Bengtsson KL. Immunomodulation by iscoms, immune stimulating complexes. Methods19(1), 94–102 (1999).
   PubMedGoogle Scholar
• Morein B, Hu K-F, Abusugra I. Current status and potential application of ISCOMs in veterinary medicine. Adv. Drug Deliv. Rev.56, 1367–1382 (2004).
   PubMed Web of Science ®Google Scholar
• Åkerblom L, Nara P, Dunlop N, Putney S, Morein B. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products. Biotechnol. Ther.4, 145–161 (1993).
   PubMedGoogle Scholar
• Morein B, Ekström J, Lövgren K. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into iscoms. J. Immunol. Methods128, 177–181 (1990).
   PubMed Web of Science ®Google Scholar
• Höglund S, Dalsgaard K, Lövgren K, Sundquist B, Osterhaus A, Morein B. ISCOMs and immunostimulation with viral antigens. In: Subcellular Biochemistry (Volume 15). Harris W (Ed.), Plenum, New York, USA 39–68 (1989).
   Google Scholar
• Reid G. Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid. Vaccine10, 597–602 (1992).
   PubMed Web of Science ®Google Scholar
• Morein B, Lövgren K, B. R, Sjölander A, Villacrés-Eriksson M. Immunostimulating complexes clinical potential in vaccine development. Clin. Immunother.3, 461–475 (1995).
   Google Scholar
• Larsson M, Lövgren K, Morein B. Immunopotentiation of synthetic oligopeptides by chemical conjugation to iscoms. J. Immunol. Methods162, 257–260 (1993).
   PubMedGoogle Scholar
• Andersson C, Sandberg L, Murby M, Sjölander A, Lövgren-Bengtsson K, Ståhl S. General expression vectors for production of hydrophobically tagged immunogens for direct iscom incorporation. J. Immunol. Methods222, 171–182 (1999).
   PubMedGoogle Scholar
• Andersson C, Sandberg L, Wernérus H, Johansson M, Lövgren-Bengtsson K, Ståhl S. Improved systems for hydrophobic tagging of recombinant immunogens for efficient iscom incorporation. J. Immunol. Methods238, 181–193 (2000).
   PubMed Web of Science ®Google Scholar
• Andersson C, Wikman M, Lövgren-Bengtsson K, Lundén A, Ståhl S. In vivo and in vitro lipidation of recombinant immunogens for direct iscom incorporation. J. Immunol. Methods255, 135–148 (2001).
   PubMedGoogle Scholar
• Andersson C, Wikman M, Lövgren-Bengtsson K, Ståhl S. Hydrophobic tagging of immunogens for iscom incorporation. In: Gene Cloning and Expression Technologies. Weiner MP, Lu Q (Eds.), Eaton Publishing, Westborough, MA, USA, 251–265 (2002).
   Google Scholar
• Wikman M, Friedman M, Pinitkiatisakul S et al. Applying biotin–streptavidin binding for iscom (immunostimulating complex) association of recombinant immunogens. Biotechnol. Appl. Biochem.41, 163–174 (2005).
   PubMedGoogle Scholar
• Wikman M, Friedman M, Pinitkiatisakul S et al. General strategies for efficient adjuvant incorporation of recombinant subunit immunogens. Vaccine23, 2331–2335 (2005).
   PubMed Web of Science ®Google Scholar
• Köhler K, Ljungquist C, Kondo A, Veide A, Nilsson B. Engineering proteins to enhance their partition coefficients in aqueous two-phase systems. Bio/Technology9, 642–646 (1991).
   PubMedGoogle Scholar
• Hassinen C, Köhler K, Veide A. Polyethylene glycol-potassium phosphate aqueous two-phase systems. Insertion of short peptide units into a protein and its effects on partitioning. J. Chromatogr. A668, 121–128 (1994).
   PubMed Web of Science ®Google Scholar
• Sjölander A, Lövgren K, Ståhl S et al. High antibody responses in rabbits immunized with influenza virus ISCOMs containing a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. Vaccine9, 443–450 (1991).
   PubMedGoogle Scholar
• Parente RA, Nir S, Szoka FCJ. pH-dependent fusion of phosphatidylcholine small vesicles. Induction by a synthetic amphipathic peptide. J. Biol. Chem.263, 4724–4730 (1988).
   PubMed Web of Science ®Google Scholar
• Nilsson B, Moks T, Jansson B et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Engineering1, 107–113 (1987).
   PubMedGoogle Scholar
• Sjölander A, Hansson M, Lövgren K, Wahlin B, Berzins K, Perlmann P. Immunogenicity in rabbits and monkeys of influenza ISCOMs conjugated with repeated sequences of the Plasmodium falciparum antigen Pf155/RESA. Parasite Immunol.15, 355–359 (1993).
   PubMedGoogle Scholar
• Makrides SC. Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev.60, 512–538 (1996).
   PubMedGoogle Scholar
• Schneewind O, Fowler A, Faull KF. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science268, 103–106 (1995).
   PubMedGoogle Scholar
• Larsson M, Brundell E, Nordfors L, Hoog C, Uhlén M, Ståhl S. A general bacterial expression system for functional analysis of cDNA-encoded proteins. Protein Expr. Purif.7, 447–457 (1996).
   PubMedGoogle Scholar
• Nilsson J, Nilsson P, Williams Y, Pettersson L, Uhlén M, Nygren P-Å. Competitive elution of protein A fusion proteins allows specific recovery under mild conditions. Eur. J. Biochem.224, 103–108 (1994).
   PubMedGoogle Scholar
• Samuelsson E, Wadensten H, Hartmanis M, Moks T, Uhlén M. Facilitated in vitro refolding of human recombinant insulin-like growth factor I using a solubilizing fusion partner. Biotechnology (NY)9, 363–366 (1991).
   PubMedGoogle Scholar
• Samuelsson E, Moks T, Nilsson B, Uhlén M. Enhanced in vitro refolding of insulin-like growth factor I using a solubilizing fusion partner. Biochemistry33, 4207–4211 (1994).
   PubMed Web of Science ®Google Scholar
• Libon C, Corvaia N, Haeuw JF et al. The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130–230 RSV-A protein. Vaccine17, 406–414 (1999).
   PubMed Web of Science ®Google Scholar
• Ghrayeb J, Inouye M. Nine amino acid residues at the NH2-terminal of lipoprotein are sufficient for its modification, processing, and localization in the outer membrane of Escherichia coli. J. Biol. Chem.259, 463–467 (1984).
   PubMedGoogle Scholar
• Laukkanen M-L, Teeri TT, Keinänen K. Lipid-tagged antibodies: bacterial expression and characterization of lipoprotein-single-chain antibody fusion protein. Protein Engineering6, 449–454 (1993).
   PubMedGoogle Scholar
• Hochuli E, Bannwarth W, Döbeli H, Gentz R, Stüber D. Genetic approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. Bio/Technology6, 1321–1325 (1988).
   Web of Science ®Google Scholar
• Ståhl S, Nilsson J, Hober S, Uhlén M, Nygren P-Å. Affinity fusions, gene expression. In: The Encyclopedia of Bioprocess Technology: Fermentation, Biocatalysis and Bioseparation. Flickinger MC, Drew SW (Eds), John Wiley and Sons Inc., New York, USA 49–63 (1999).
   Google Scholar
• Burg JL, Perelman D, Kasper LH, Ware PL, Boothroyd JC. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. J. Immunol.141, 3584–3591 (1988).
   PubMed Web of Science ®Google Scholar
• Harning D, Spenter J, Metsis A, Vuust J, Petersen E. Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulin M (IgM) and IgG antibodies. Clin. Diagn. Lab. Immunol.3, 355–357 (1996).
   PubMedGoogle Scholar
• Savage D, Mattson G, Desai S, Nielander G, Morgensen S, Conklin E. Avidin-Biotin Chemistry: A Handbook. Pierce Chemical Company, Rockford, IL, USA (1992).
   Google Scholar
• Schatz PJ. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Bio/Technology11, 1138–1143 (1993).
   PubMedGoogle Scholar
• Nilsson J, Ståhl S, Lundeberg J, Uhlén M, Nygren P-Å. Affinity fusion strategies for detection, purification, and immobilization of recombinant proteins. Protein Expr. Purif.11, 1–16 (1997).
   PubMed Web of Science ®Google Scholar
• Howe DK, Crawford AC, Lindsay D, Sibley LD. The p29 and p35 immunodominant antigens of Neospora caninum tachyzoites are homologous to the family of surface antigens of Toxoplasma gondii. Infect. Immun.66, 5322–5328 (1998).
   PubMedGoogle Scholar
• Pinitkiatisakul S, Mattsson JG, Wikman M et al. Immunisation of mice against neosporosis with recombinant NcSRS2 iscoms. Vet. Parasitol.129, 25–34 (2005).
   PubMedGoogle Scholar
• Saviranta P, Haavisto T, Rappu P, Karp M, Lövgren T. In vitro enzymatic biotinylation of recombinant fab fragments through a peptide acceptor tail. Bioconjug. Chem.9, 725–735 (1998).
   PubMedGoogle Scholar